Standard care relies on LDL-C thresholds, single-gene panels, PSA, and family history. But millions of people carry inherited risk that these tools fail to capture.
Allelica combines genome-wide polygenic risk scores with standard clinical risk models to identify:
These high-risk patients are where prevention has the biggest impact.
Allelica offers state-of-the-art tools designed to integrate genetics into clinical practice to reduce the burden of common disease. We enable physicians to provide cutting-edge personalized risk assessments across a range of conditions. The Allelica platform enhances traditional care with comprehensive genetic insights, allowing for more precise, evidence-based interventions.
Allelica’s PRS are validated and calibrated for people of diverse ancestry and admixed background. Each Allelica test starts with a precise genetic ancestry analysis, so results do not rely on error-prone self-reported ethnicity. Depending on the condition and the ancestry analyzed, Allelica PRS are built using thousands to millions of genetic variants across the whole genome. These variants are distributed genome-wide, including intergenic regions as well as regulatory elements such as promoters and enhancers, enabling comprehensive modeling of the biological cascades underlying disease risk.
In this webinar, Dr. Douglas Jacoby, Medical Director of the Penn Medicine Center for Preventive Cardiology and Lipid Management, discusses his experience prescribing PRS testing for patients and how he uses results to improve clinical management.
Discover how Allelica Multi-Ancestry Polygenic Risk Score help clinicians uncover hidden risk, guide treatment decisions, and improve patient outcomes.
"This testing made a huge difference for both myself and my patient. Having a more complete understanding of her individualized risk helped support a much more confident clinical decision."
Stone Oak Women's Center
"PRS has become a "tie-breaker" for clinical decision-making in patients with uncertain risk profiles, giving us the confidence we need to make the most effective treatment decisions."
Intermountain Medical Center
"PRS testing helps guide decisions in uncertain cases, brings clarity to patients with unexplained events, and facilitates more personalized, thoughtful discussions about risk."
Hamilton Cardiology Associates
Allelica’s Breast Risk Reveal™ seamlessly integrates monogenic mutation analysis, multi-ancestry polygenic risk scores, and established clinical models like Tyrer-Cuzick and BOADICEA to deliver the most comprehensive and individualized view of hereditary breast cancer risk. By combining genetic and clinical risk factors, our approach improves risk estimates for both mutation carriers and non-carriers. This enables clinicians to better identify women who can benefit from enhanced surveillance or preventive strategies, across all ancestries.
Discover how leading providers like Dr. Rigved Tadwalkar of the Pacific Heart Institute are using Allelica’s PRS test to proactively prevent heart attacks.
"Allelica's polygenic panel is a powerful tool that offers a unique window into one's genetic risk for the most important diseases in medicine. The literature shows that polygenic profiles augment conventional risk assessments, and I've seen it first hand. If we're serious about personalized medicine, we need to discuss tests like this with our patients."
"Allelica's polygenic risk scoring has transformed my cardiology practice, allowing us to quantify the genetic contribution to cardiovascular risk-- something we could not easily measure before. This breakthrough has enabled more comprehensive and personalized care, integrating genetic data into risk assessments with precision we never had access to previously."
Allelica’s advanced PRS technology equips physicians with the tools needed to advance precision medicine. By incorporating genetic risk scores into routine practice, you can identify high-risk patients across multiple disease categories, tailor interventions more effectively, and lead the way in personalized healthcare.
Allelica’s bioinformatics platform empowers clinical laboratories to bring multi-ancestry PRS and advanced genomic testing in-house with confidence. Available as both cloud-based and on-premise solutions when data cannot leave the building. Allelica software is designed for seamless integration into your existing workflows. With customizable panels and multilingual, white-label reporting, Allelica provides the flexibility and scalability needed to meet your lab’s specific needs while maintaining the highest standards of security and performance. Elevate your lab's capabilities with Allelica’s advanced, adaptable tools.
Allelica’s multi-ancestry PRS trial stratification platform helps pharmaceutical and biotech companies shorten trial timelines, reduce participant numbers , and test more programs within the same budget . By integrating cutting-edge genetics and AI-driven analytics, we identify the right patients for each study, increasing statistical power and maximizing the likelihood of success. Our approach also enables companies to salvage underperforming or failed trials by uncovering subpopulations of patients who benefit most from a given therapy, turning potential setbacks into actionable insights. From trial design to execution, our comprehensive tools and expertise ensure your clinical programs are faster, leaner, and more cost-effective , accelerating the path to market for transformative therapies.
CLIA registration number: 22D2315916
Allelica CEO presents at PMWC 2025
Among global leaders in healthcare innovation at the Precision Medicine World Conference 2025, Allelica CEO Giordano Bottà will present how clinical multi-ancestry polygenic risk score testing empowers physicians to prevent heart attacks.
Allelica obtains CLIA Certification
Allelica has officially received its CLIA number, marking a key milestone in delivering clinically validated genetic testing. This certification enables the company to offer high-quality polygenic risk score testing for improved patient care.
Thermo Fisher selects Allelica as PRS partner
Allelica’s PRS software and reports are now compatible with Thermo Fisher Scientific’s Axiom™ human genotyping arrays. This integration streamlines PRS implementation, enabling more efficient and scalable genetic risk assessment for clinical and research applications.
Allelica partners with Baylor College of Medicine
Allelica will provide its multi-ancestry polygenic risk score (PRS) technology to Baylor College of Medicine for clinical implementation. This collaboration advances precision medicine by integrating PRS into patient care, improving risk assessment across diverse populations.
Allelica multi-ancestry PRS published in Nature Communications
Results published by Allelica scientists in Nature Communications demonstrate the clinical utility of polygenic risk scores across multiple ancestry groups.The publication adds to growing evidence of the clinical value of PRS in cardiovascular disease risk assessment, showing that adding PRS to traditional models improves their precision and accuracy.
Baylor & Allelica present clinical workflow for PRS testing at ASHG
Allelica presented collaborative results with Baylor College of Medicine at the American Society of Human Genetics Annual Meeting 2023. George Busby, Allelica CSO, presented the results in the poster titled “Complete end-to-end workflow for implementing clinical polygenic risk scores”.
Allelica launches the Allelica Precision Server
Allelica announces the release of the Allelica Precision Server (APS) for CLIA-compliant, on-premises analysis and clinical reporting of polygenic risk score, pharmacogenomics and carrier screening. APS is now available for medical laboratories and healthcare providers.
Allelica participates in BiotechX Europe 2023
The Allelica team met with leaders in the pharmaceutical industry and biotechnology at the annual BioTechX conference in Basel, Switzerland. PRS is increasingly gaining traction among pharma and biotech companies for its ability to stratify clinical trial populations and identify new drug targets.
PRS cost-effectiveness results published in Frontiers
Results published by Allelica researchers in Frontiers in Public Health reveal that integrating PRS testing into workplace health programs cuts costs for employers and improves quality of life for employees. Authors found that Allelica's workplace program integrating PRS with the standard of care, cardioriskSCORE, significantly outperformed programs without PRS.
Allelica delivers oral presentation, three poster presentations at ESHG 2023
The Allelica team showcased exciting PRS results at the European Society of Human Genetics Conference 2023. Posters included: Low-coverage genotyping-by-sequencing with accurate long HiFi reads and optimized imputation (presented in collaboration with PacBio), Recalibrating polygenic risk scores to country-specific incidence, and Analyses of polygenic risk scores that consider individual-level admixture proportions outperform single ancestry approaches.
Clinical breast cancer PRS Results presented at ASCO 2023
Dr. Daniel Morganstern of Hartford Healthcare presented results integrating Allelica’s multi-ancestry PRSs into risk assessments at the American Society of Clinical Oncology Annual Meeting. Findings revealed the value PRS provides in clinical risk assessments for breast cancer.
Allelica Research Published in the Journal of the American Heart Association
A health economics study [Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk‐Enhancing Factor in the Pooled Cohort Equation: A Cost‐Effectiveness Analysis Study] has been published in the Journal of the American Heart Association. The study, performed by Allelica, in collaboration with experts from Illumina and the University of Sydney, analyzed the cost-effectiveness of PRS in heart disease risk assessments and found that PRS is cost-saving in US health systems.
Allelica CAD PRS Research in Circulation
Allelica researchers identified a critical interaction between PRS for coronary artery disease (CAD) and LDL cholesterol level. Their discovery has major implications for clinical decision-making in primary prevention strategies. The research is now available in the American Heart Association Journal, Circulation.
Allelica Obtains ISO Certification
Allelica continues to set the industry standard of clinical-grade Polygenic Risk Score analysis with the addition of two key ISO certifications. ISO 13485 and ISO 9001 certify that Allelica applies medical device quality management processes every step of the way.
Data Driven Our products are developed and validated using world class datasets and state-of-the-art technology to ensure the highest level of quality.
Scientific Rigor We are a group of international scientists and researchers committed to maintaining standards of academic excellence every step of the way.
Human-centricity Everything we do works towards our common goal of providing tangible improvement in preventive healthcare to help humans live a longer, healthier life.
